Sanofi Stock News

French drugmaker Sanofi on Wednesday said it would stop immediately any new spending not related to the supply of essential and life-changing medicines and vaccines in Russia, as well as in Belarus.

Sanofi SA (NASDAQ: SNY ) and Seagen Inc (NASDAQ: SGEN ) have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi''s proprietary monoclonal antibody (mAb) technology and Seagen''s proprietary … Full story available on Benzinga.com

Sanofi (SNY) and Seagen (SGEN) signed an exclusive collaboration agreement to develop and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets.The…

Sanofi (SNY) is developing a subcutaneous formulation of its myeloma drug, Sarclisa. A pivotal study is expected to start in the second half of 2022.

BOTHELL, Wash. & PARIS--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Sanofi today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein and Sanofi currently has

Sanofi (SNY) and Blackstone (BX) entered a €300M collaboration to advance an innovative treatment for multiple myeloma ((MM)).The company said funds managed by Blackstone Life…

Sanofi's (SNY) phase II AMEERA-3 study, investigating amcenestrant in ER+/HER2- advanced/metastatic breast cancer, fails to meet the primary endpoint.

Futures Fade As Yields Soar, Oil Slides And China Stocks Crater US equity futures held on to modest gains overnight as the market desperately clung on to hope that the latest ceasefire talks between Russia and Ukraine which started on Monday, may yield results (clearly forgetting how the rug was pulled from under the market on Friday in an identical setup), which initially sent stocks higher especially in Europe, despite a surge in 10Y TSY yields to 2.10%, the highest since July 2019, two days ahead of the first Fed rate hike, and a complete collapse in Chinese stocks. And while U.S. index futures were still pointing to a positive open with negotiations between Russia and Ukraine set to continue, this gain is fading fast, with spoos now up just 0.5% after rising 1% earlier… ... as headlines from the Kremlin suggested that a ceasefire is the last thing on Putin''s mind. *KREMLIN: RUSSIA WILL REALIZE ALL ITS PLANS IN UKRAINE OPERATION *KREMLIN: UKRAINE OPERATION WILL BE COMPLETED ON SCHEDULE *KREMLIN: RUSSIA DIDN''T REQUEST CHINA MILITARY AID FOR OPERATION *KREMLIN: RUSSIA HAS RESOURCES NEEDED TO COMPLETE UKRAINE ACTION And while futures would normally be deep in the red by now, and will be shortly now that AAPL is at LOD...

Sanofi SA (NASDAQ: SNY ) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer, failed to slow the progression of the disease in the Phase 2 AMEERA-3 trial. Results from the Phase 2 trial showed that the drug amcenestrant, given as a … Full story available on Benzinga.com

Sanofi SA (NASDAQ: SNY ) stock slid after … Full story available on Benzinga.com

Sanofi''s (SNY) oral medicine amcenestrant failed to meet the main goal of progression-free survival ((PFS)) in a phase 2 trial to treat patients with a type of advanced breast…

© Reuters. Sanofi logo at the company’s headquarters during the annual results news conference in Paris, France, February 4, 2022. REUTERS/Benoit Tessier/Files (Reuters) – Shares in Sanofi (NASDAQ:) slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the …

https://www.investing.com/news/stock-market-news/sanofi-shares-drop-on-trial-setback-for-breast-cancer-pill-2783837

(Reuters) – Shares in Sanofi slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the disease in a clinical trial. Results from the Phase II AMEERA-3 clinical trial, keenly awaited by Sanofi investors, showed that the drug amcenestrant, … Read More

Sanofi’s experimental cancer medicine amcenestrant failed in an intermediate clinical test for breast cancer, dealing a blow to one of the French drugmaker’s potential future blockbusters.